Press Releases

A comprehensive library of Ipsen media releases for investors and members of the press.

Key highlights

Explore more press releases

Filter

Topics

Period

Filter by

recent search

Showing: 1 – 05 of 30 Press Releases

Ipsen completes acquisition of Albireo,  expanding the scope of its Rare Disease portfolio
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

PARIS, FRANCE, 3 March 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s


Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

PARIS, FRANCE, 22 February 2023 – Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Anemone Acquisition Corp. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to


Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs
Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

PARIS, FRANCE, MONTREAL, CANADA 15 February 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), Université de Montréal and IRICoR announce that Ipsen has exercised its option to acquire exclusive rights to a pre-clinical stage program with potential oncolog


Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

CORRECTED and REPLACING: Minor updates were made on 24 April 2023 to correct an error in the original data analysis impacting the blinded independent central reviewer (BICR)-assessed data points (PFS, ORR, and DoR). The safety and efficacy profile, includi


Ipsen presents strong full-year 2022 results and guidance for 2023
Ipsen presents strong full-year 2022 results and guidance for 2023

Paris (France), 9 February 2023


1 2 3 4 5 6

Your dedicated contacts